financetom
Business
financetom
/
Business
/
Alkermes Q2 Earnings, Revenue Fall; Reiterates 2025 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alkermes Q2 Earnings, Revenue Fall; Reiterates 2025 Guidance
Jul 29, 2025 4:55 AM

07:43 AM EDT, 07/29/2025 (MT Newswires) -- Alkermes ( ALKS ) reported Q2 earnings Tuesday of $0.52 per diluted share, down from $0.53 a year earlier.

Analysts polled by FactSet expected $0.24.

Total revenue for the quarter ended June 30 was $390.7 million, compared with $399.1 million a year earlier.

Analysts surveyed by FactSet expected $341.4 million.

The company reiterated its total revenue guidance of $1.34 billion to $1.43 billion. Analysts surveyed by FactSet expect $1.38 billion.

Shares of the company were up 5.5% in Tuesday's premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kraken Robotics Raises $51.75 Million in Bought Deal Offering
Kraken Robotics Raises $51.75 Million in Bought Deal Offering
Oct 22, 2024
10:32 AM EDT, 10/22/2024 (MT Newswires) -- Kraken Robotics ( KRKNF ) on Tuesday closed its bought deal offering, raising $51.75 million, including the full exercise of the over-allotment option. The company issued 32.34 million shares at $1.60 each. A statement noted the net proceeds of the Offering are expected to be used to advance the company's long-term strategy, including:...
Akebia Therapeutics Signs Contract to Expand Vafseo Access for Patients on Dialysis; Shares Rise
Akebia Therapeutics Signs Contract to Expand Vafseo Access for Patients on Dialysis; Shares Rise
Oct 22, 2024
10:34 AM EDT, 10/22/2024 (MT Newswires) -- Akebia Therapeutics ( AKBA ) said Tuesday it signed a commercial contract with a kidney care services provider to help expand access to Vafseo, or vadadustat, for patients on dialysis. Vafseo is indicated to treat anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months,...
EMX Royalty Agrees to Sell Polymetallic Project in Sweden to Alpha Future Funds
EMX Royalty Agrees to Sell Polymetallic Project in Sweden to Alpha Future Funds
Oct 22, 2024
10:35 AM EDT, 10/22/2024 (MT Newswires) -- EMX Royalty ( EMX ) said Tuesday it has executed an exploration and option agreement to sell its Gumsberg polymetallic project in Sweden to private investment firm Alpha Future Funds. At closing, EMX said it would get $100,000 and Alpha could acquire the entire project by meeting work commitments by the end of...
NeoGenomics Gets Conditional Approval for Cancer Tests in New York
NeoGenomics Gets Conditional Approval for Cancer Tests in New York
Oct 22, 2024
10:36 AM EDT, 10/22/2024 (MT Newswires) -- NeoGenomics ( NEO ) said Tuesday that the New York State Department of Health granted conditional approval for the company's Neo Comprehensive Solid Tumor assay and NeoType DNA & RNA Lung tests. The approval allows for commercial access in New York, the provider of oncology testing services said. NeoGenomics ( NEO ) shares...
Copyright 2023-2026 - www.financetom.com All Rights Reserved